Does Blue Cross Blue Shield Cover Trulicity?

How BCBS Formulary Placement Works for Trulicity

Blue Cross Blue Shield is not one insurer. It is a federation of 34 independent companies operating across all 50 states, the District of Columbia, and Puerto Rico. Each affiliate maintains its own formulary, which is the list of medications it covers and the cost-sharing tier assigned to each drug. That structure means a Trulicity prescription filled under BCBS of Texas may carry a different copay than the same prescription under BCBS of Massachusetts.

Trulicity generally lands on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) across most BCBS affiliate formularies. Preferred-brand placement usually means a copay between $25 and $75 after deductible, while non-preferred placement can mean $100 to $300 or coinsurance of 25% to 50% of the drug's negotiated price. The distinction depends on the pharmacy benefit manager (PBM) contract each affiliate holds with Eli Lilly and on whether a competing GLP-1 (such as semaglutide or liraglutide) has secured a more favorable rebate arrangement. The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line therapy after metformin in patients with established atherosclerotic cardiovascular disease (ASCVD) or high CV risk, which supports formulary inclusion across payers [1].

To find your specific tier, log in to your BCBS member portal or call the number on the back of your card and ask the pharmacy benefits department for the formulary status of dulaglutide.

Prior Authorization Requirements

Most BCBS affiliates require prior authorization (PA) before they will pay for Trulicity. PA is a utilization management tool that asks your prescriber to submit clinical documentation proving the drug is medically necessary for your situation. The process typically takes 24 to 72 hours for a standard request, though urgent requests can be expedited within 24 hours.

Common PA criteria across BCBS plans include a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), a recent A1C value at or above 7.0% despite lifestyle modifications and at least 90 days of metformin therapy at maximally tolerated doses, and prescribing by or in consultation with an endocrinologist or primary care physician experienced in diabetes management. Some affiliates also require documentation that the patient has no history of medullary thyroid carcinoma or MEN 2 syndrome, consistent with the FDA boxed warning on all GLP-1 receptor agonists [2].

A 2023 analysis published in Diabetes Care found that prior authorization for GLP-1 receptor agonists delayed treatment initiation by a median of 17 days and was associated with a 22% rate of treatment abandonment, meaning patients never filled the prescription after the initial denial or delay [3]. If your PA is denied, you have the right to appeal. The first step is an internal appeal through BCBS, followed by an external review by an independent review organization (IRO) if the internal appeal is unsuccessful.

Step Therapy and Preferred Alternatives

Step therapy is a related but distinct coverage requirement. Where PA asks "is this drug appropriate?", step therapy asks "has the patient tried less expensive options first?" BCBS plans that impose step therapy for Trulicity typically require documented use of metformin, and sometimes a sulfonylurea or SGLT2 inhibitor, before approving the GLP-1 class.

The Endocrine Society Clinical Practice Guideline on pharmacologic treatment of type 2 diabetes states: "GLP-1 receptor agonists should be considered early in the treatment algorithm for patients with type 2 diabetes, particularly those with established ASCVD, heart failure, or chronic kidney disease, rather than reserving them as third- or fourth-line agents" [4]. This guideline language can be valuable ammunition in a step therapy exception request.

Some BCBS affiliates prefer a different GLP-1 over Trulicity. BCBS of Illinois, for example, has historically placed semaglutide (Ozempic) on a preferred tier while assigning Trulicity to non-preferred status. Others do the reverse. When your plan prefers a competing GLP-1, your prescriber can request a formulary exception if there is a clinical reason you need Trulicity specifically, such as a documented adverse reaction to the preferred agent or a contraindication.

What Trulicity Costs with BCBS Insurance

Out-of-pocket cost depends on four variables: your plan's formulary tier for Trulicity, your annual deductible (and whether you have met it), your plan's cost-sharing structure (copay vs. coinsurance), and whether you are in the coverage gap (for Medicare Part D plans administered by BCBS).

For commercially insured BCBS members with Trulicity on a preferred brand tier, typical monthly costs range from $25 to $75 after deductible. Non-preferred placement raises that to $100 to $300. High-deductible health plans (HDHPs) paired with HSAs may require full list price until the deductible is met, which at Trulicity's wholesale acquisition cost of approximately $1,029.35 per month can be a significant barrier [5].

Eli Lilly offers a manufacturer savings card that can reduce the copay to as little as $25 per month for eligible commercially insured patients. The card cannot be used with government-funded insurance (Medicare, Medicaid, Tricare, VA). The savings program typically covers up to $150 per fill, with a maximum annual benefit that resets each calendar year.

For BCBS Medicare Advantage or Medicare Part D plans, Trulicity coverage follows CMS formulary guidelines. The Centers for Medicare & Medicaid Services requires Part D plans to cover all or substantially all drugs in the diabetes class [6]. Under the Inflation Reduction Act, Medicare Part D out-of-pocket costs for insulin and certain diabetes drugs are capped, though GLP-1 receptor agonists prescribed solely for diabetes (not weight management) may still carry coinsurance during the coverage gap phase.

Clinical Evidence Supporting Coverage

Insurers weigh clinical trial data when making formulary decisions. Trulicity has a strong evidence base across the AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial program and the REWIND cardiovascular outcomes trial.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 12% compared with placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99, P=0.026) over a median follow-up of 5.4 years [7]. This trial was notable because it enrolled a broader population than earlier GLP-1 CV outcomes trials: 69% of participants had cardiovascular risk factors but no established CV disease at baseline.

In the AWARD-11 trial, dulaglutide at the higher 4.5 mg dose achieved a mean A1C reduction of 1.87% from a baseline of 8.6%, compared with 1.54% for the 1.5 mg dose [8]. The FDA approved the 3.0 mg and 4.5 mg doses in 2020, giving prescribers dose-escalation flexibility that was previously unavailable with this agent [5].

Dr. Hertzel Gerstein, principal investigator of the REWIND trial and professor of medicine at McMaster University, noted: "The cardiovascular benefits of dulaglutide extend to a broad population of people with type 2 diabetes, including those who have not yet developed overt cardiovascular disease" [7]. This finding strengthened the case for insurers, including BCBS affiliates, to cover Trulicity without restricting it to secondary prevention populations only.

How to Get Trulicity Approved if BCBS Denies Coverage

Denial is not the end of the road. A structured appeals process exists, and persistence pays off. Industry data suggest that 40% to 60% of first-level internal appeals for GLP-1 receptor agonists result in a reversal of the initial denial.

Start by asking your prescriber's office for the specific denial reason. The most common reasons are failure to meet step therapy requirements, incomplete documentation, or the drug being classified as non-formulary. Each reason has a corresponding strategy.

For step therapy denials, your prescriber should submit a step therapy exception request. This form documents why the preferred alternatives are clinically inappropriate for you. Valid reasons include prior adverse reactions (e.g., documented GI intolerance to the preferred GLP-1), contraindications (e.g., personal or family history of medullary thyroid carcinoma if the preferred agent carries a different risk profile), or clinical evidence that the specific agent is more appropriate for your comorbidity profile.

For incomplete documentation, the fix is straightforward: resubmit with the missing lab values, diagnosis codes, or treatment history. Your prescriber's office should include recent A1C results (within 90 days), a medication history showing metformin trial, and the specific ICD-10 and NDC codes.

For non-formulary denials, request a formulary exception (also called a coverage determination). The ADA's position statement on insulin affordability and access emphasizes that cost-related barriers to glucose-lowering medications contribute to therapeutic inertia and worse glycemic outcomes [1]. Citing this in the appeal letter, alongside the patient-specific clinical rationale, strengthens the case.

If the internal appeal fails, you can request an external review. Under the Affordable Care Act, all non-grandfathered plans must offer external review by an independent third party. The external reviewer is not employed by BCBS and evaluates the case based on clinical evidence and plan terms.

Trulicity vs. Other GLP-1s on BCBS Formularies

BCBS formulary decisions often pit Trulicity against Ozempic (semaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide). Understanding where each sits on your plan's formulary can save hundreds of dollars per month.

Ozempic has gained preferred status on many BCBS formularies following the SUSTAIN-6 trial (N=3,297), which showed semaglutide 0.5 mg and 1.0 mg reduced major adverse cardiovascular events (MACE) by 26% vs. placebo (HR 0.74, 95% CI 0.58 to 0.95) over 2.1 years [9]. The larger relative risk reduction compared with REWIND's 12% has influenced some PBM negotiations in Ozempic's favor.

Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, demonstrated superior A1C reduction and weight loss compared with semaglutide 1.0 mg in the SURPASS-2 trial (N=1,879). Tirzepatide 15 mg achieved a mean A1C reduction of 2.30% vs. 1.86% for semaglutide 1.0 mg [10]. Some BCBS affiliates have added tirzepatide to formularies at a preferred tier, potentially displacing both Trulicity and Ozempic.

Victoza (liraglutide 1.8 mg daily) is the oldest GLP-1 in this group and sometimes occupies a lower tier due to longer market history and potentially more favorable rebate terms. The trade-off is daily injection frequency vs. Trulicity's weekly dosing.

If your BCBS plan covers one GLP-1 but not Trulicity, and you have a clinical reason to prefer dulaglutide, document that reason clearly. Some patients tolerate one GLP-1 better than another. GI side effects (nausea, vomiting, diarrhea) vary across agents, and a documented trial-and-failure of the preferred agent is the most effective basis for an exception request.

BCBS Coverage for Off-Label Trulicity Use

Trulicity is FDA-approved for type 2 diabetes and CV risk reduction in T2D patients with established cardiovascular disease. It is not FDA-approved for weight management, unlike semaglutide 2.4 mg (Wegovy) or tirzepatide (Zepbound). BCBS plans will generally not cover Trulicity if the sole indication is weight loss.

Some prescribers attempt off-label use for obesity in patients without a diabetes diagnosis. BCBS affiliates almost universally deny these claims because the prescribing indication does not match the FDA-approved labeling. The FDA's approved labeling for dulaglutide specifies use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [5].

If weight management is the primary goal and your prescriber believes a GLP-1 is appropriate, ask about Wegovy or Zepbound. BCBS coverage for anti-obesity medications is expanding but remains inconsistent across affiliates. As of early 2026, roughly half of BCBS affiliates cover at least one FDA-approved anti-obesity medication under specific clinical criteria (BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity).

Tips to Minimize Your Out-of-Pocket Cost

Reducing what you pay for Trulicity requires working multiple angles simultaneously. Check your plan's formulary first. If Trulicity is non-preferred but another GLP-1 is preferred, discuss switching with your prescriber. The clinical differences between GLP-1 agents are real but modest for most patients, and saving $200 per month may outweigh marginal efficacy differences.

Enroll in Eli Lilly's Trulicity Savings Card if you carry commercial insurance. The card works at the pharmacy counter and is compatible with most BCBS commercial plans. It does not work with Medicare, Medicaid, or other government programs.

For Medicare Part D members, check whether your plan has entered an Enhanced Part D benefit structure under the Inflation Reduction Act. The $2,000 annual out-of-pocket cap on Part D spending, fully effective as of 2025, limits total yearly exposure across all Part D medications, including Trulicity [6].

Ask your prescriber about samples. Eli Lilly provides starter samples to physicians' offices, which can bridge a gap during the PA process. Using samples during the 2- to 3-week PA review window prevents a lapse in treatment.

Compare pharmacy pricing. BCBS plans often have preferred pharmacy networks where copays are lower. Mail-order pharmacy benefits frequently offer a 90-day supply for the cost of two monthly copays, which translates to a 33% savings on cost-sharing.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement notes: "Financial barriers remain a leading cause of GLP-1 receptor agonist discontinuation, with approximately 30% of patients abandoning therapy within the first year due to cost" [11]. Proactively addressing coverage and cost before starting therapy reduces the risk of an avoidable interruption.